Nitric oxide (NO) is a major effector molecule in cancer prevention. A number of studies have shown that NO prodrug JS-K (O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) induces apoptotic cell death in vitro and in vivo, indicating that it is a promising new therapeutic for cancer. However, the mechanism of its tumor-killing activity remains unclear. Ubiquitin plays an important role in the regulation of tumorigenesis and cell apoptosis. Our earlier report has shown that inactivation of the ubiquitin system through blocking E1 (ubiquitin-activating enzyme) activity preferentially induces apoptosis in p53-expressing transformed cells. As E1 has an active cysteine residue that could potentially interact with NO, we hypothesized that JS-K could inactivate E1 activity. E1 activity was evaluated by detecting ubiquitin-E1 conjugates through immunoblotting. JS-K strikingly inhibits the ubiquitin-E1 thioester formation in cells in a dose-dependent manner with an IC 50 of approximately 2 lM, whereas a JS-K analog that cannot release NO did not affect these levels in cells. Moreover, JS-K decreases total ubiquitylated proteins and increases p53 levels, which is mainly regulated by ubiquitin and proteasomal degradation. Furthermore, JS-K preferentially induces cell apoptosis in p53-expressing transformed cells. These findings indicate that JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.
Nitric oxide (NO) plays a critical role in numerous signaling pathways and induces a wide variety of biological effects. Several reports have shown that NO induces cell apoptosis and inhibits tumorigenesis (Ying and Hofseth, 2007) . However, NO has limited solubility in water and is unstable in the presence of various oxidants. Therefore, utilizing chemical agents with stable NO release is an effective approach to analyse the function of NO. One such effective NO prodrug is JS-K.
JS-K (O 2 -(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl) piperazin-1-yl]diazen-1-ium-1,2-diolate) ( Figure 1a ) is a diazeniumdiolate prodrug designed to release NO when metabolized by glutathione S-transferase. Several studies have shown that JS-K inhibits cell growth and invasion and induces apoptosis in a variety of tumors and leukemias in vitro (Ren et al., 2003; Shami et al., 2003 Shami et al., , 2006 Liu et al., 2004; Kiziltepe et al., 2007; Simeone et al., 2008) . In addition, administration of JS-K inhibits the growth of tumors, including leukemias, in animal models and significantly increases the survival of these animals (Shami et al., 2003 (Shami et al., , 2006 Kiziltepe et al., 2007) . These findings suggest that JS-K could be a lead compound for anti-tumor therapeutics. However, the mechanism of its tumor-killing activity remains unclear.
Ubiquitin is a highly conserved 76-amino acid protein. Modification of a target substrate with ubiquitin is catalysed in sequential steps by three enzymes. In the first step, ubiquitin-activating enzyme (E1) forms a ubiquitin-adenylate intermediate that serves as a donor of ubiquitin to an active site cysteine of the E1 in a thioester linkage. Subsequently, ubiquitin is transferred to ubiquitin-conjugating enzyme (E2) and then to ubiquitin ligase (E3). The substrates that are recognized by the 26S proteasome are usually conjugated to a lysine-48 (K48)-linked polyubiquitin chain. Ubiquitin-mediated degradation of target proteins through the proteasome pathway plays an important role in the control of numerous functions, including signal transduction, transcriptional regulation, stabilization of short-lived protein and cell apoptosis. Abnormalities in ubiquitin-mediated processes have been observed in some pathological conditions, including malignant transformation (Hershko and Ciechanover, 1998) . Moreover, our earlier study has shown that inactivation of the ubiquitin system through blocking E1 activity causes accumulation of p53 and preferential cell apoptosis in transformed cells and cells harboring wild-type p53 (Yang et al., 2007) . Therefore, controlling the ubiquitin system by blocking E1 activity could be an effective strategy for cancer therapy.
Several studies have determined that NO modifies active cysteine residues (Lipton, 1999) . As E1 has such a residue, we hypothesized that the NO prodrug JS-K could inactivate E1 activity through interaction with this residue. To investigate our hypothesis, we first examined S-nitrosylation of E1. Tert-immortalized human retinal pigment epithelial (RPE) cells were treated with JS-K or a JS-K analog JS-43-126, which cannot release NO ( Figure 1a ) (Simeone et al., 2008) . After this incubation, S-nitrosylation of E1 was assessed by a biotin switch assay (Jaffrey et al., 2001) . As a result, E1 was readily S-nitrosylated by JS-K but not JS-43-126 (Figure 1b  compare lanes 3 and 4) . Next, the E1 activity after JS-K treatment was evaluated by detecting ubiquitin-E1 thioesters through immunoblotting under either reducing (with DTT) or non-reducing (without DTT) conditions. JS-K markedly reduced ubiquitin-E1 thioesters in a concentration-dependent manner (Figure 1c) . The IC 50 of JS-K on inhibition of ubiquitin-E1 thioesters was approximately 2 mM. To confirm that NO released by JS-K inhibits E1 activity, a different NO prodrug PABA/ NO was utilized (Figure 1a) . PABA/NO also decreased the level of ubiquitin-E1 conjugation in cells in a concentration-dependent manner (Figure 1d ). To further evaluate the effect of NO on ubiquitin-E1 thioesters in cells, JS-43-126 was used. JS-K reduced ubiquitin-E1 thioesters, whereas JS-43-126 had no effect on these levels (Figure 1e , compare lanes 3 and 5). These data indicate that JS-K blocks E1 activity in a concentration-dependent manner.
Next, the effect of JS-K on the accumulation of total cellular ubiquitylated proteins was analysed. RPE cells were exposed to JS-K, and total ubiquitylation was assessed. JS-K clearly decreased the accumulation of To further analyse the inactivation of E1 by JS-K, the degradation of b-catenin was assessed. b-Catenin controls both cadherin-mediated cell adhesion and activation of Wnt target genes. In the absence of Wnt signals, b-catenin is ubiquitylated, after phosphorylation by glycogen synthase kinase 3b and casein kinase 1a, and degraded through the proteasome pathway (Kimelman and Xu, 2006) . To investigate the effect of JS-K on cellular b-catenin levels, HEK293 cells that express wild-type b-catenin were used. The cells were exposed to JS-K, and b-catenin levels in cells were analysed by immunoblotting. JS-K accumulated cellular b-catenin similar to that seen with the proteasome inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN) (Adams, 2004) (Figure 2b ).
Programmed cell death 4 (Pdcd4) is a tumor suppressor protein that inhibits transformation in vitro and tumor formation in vivo (Jansen et al., 2005) . Recent studies have shown that Pdcd4 is ubiquitylated through S6K1-and bTRCP-mediated proteasomal degradation (Dorrello et al., 2006) . To analyse whether JS-K causes the accumulation of Pdcd4, A549 cells whose Pdcd4 levels are relatively low were treated with JS-K, and Pdcd4 levels in cells was assessed. JS-K increased cellular Pdcd4 levels (Figure 2c) .
Nuclear factor-kB (NF-kB) is a transcriptional factor that plays an important role in inflammation and tumorigenesis. IkBa is an inhibitor of NF-kB that acts by binding to its nuclear localization sequence. In the presence of an activator of NF-kB such as IL-1a, IkBa is ubiquitylated, after phosphorylation by IkB kinase (Ikk) family proteins, and degraded through proteasome degradation (Chen, 2005) . To show that JS-K reduces degradation of IkBa, HeLa cells that express wild-type IkBa were incubated with JS-K prior to treatment with IL-1a. JS-K strikingly delayed IL-1a-induced degradation of IkBa and phosphorylated IkBa levels in cells (Figure 2d, compare lanes 3 and 6) . These data clearly support the notion that JS-K blocks the activity of ubiquitylation and degradation of proteins.
The tumor suppressor p53 mainly functions as a transcription factor to control the expression of a variety of target genes, leading to growth arrest, senescence and apoptosis. p53 selectively kills transformed cells by inducing apoptosis. The cellular level of p53 is tightly controlled through proteasomal degradation and is very low in normal cells. One of the essential proteins involved in regulating cellular p53 levels is mouse double minute2 (Mdm2, human ortholog is named Hdm2). Hdm2 is an E3 that ubiquitylates p53 and auto-ubiquitylates itself, resulting in proteasomal degradation of both proteins (Yang et al., 2004) . We predicted that JS-K would inhibit Hdm2-mediated p53 ubiquitylation, leading to the accumulation of p53. To determine the ability of JS-K to increase p53 and Hdm2 levels, RPE cells were incubated with JS-K, and cellular (Yang et al., 2005) . Total ubiquitylation in cells and b-Actin was immunoblotted using anti-ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-b-Actin antibodies. (b) JS-K increases cellular b-catenin levels. HEK293 cells were serum starved for 17 h. Later, the cells were exposed to 20 mM ALLN (Calbiochem) or 10 mM JS-K for 2 h. Cell lysates were prepared as described earlier (Giarre et al., 1998) . Samples were assessed by immunoblotting using b-catenin (Santa Cruz Biotechnology) and b-Actin antibodies. p53 and Hdm2 levels were assessed. Characteristic of a proteasome inhibitor, ALLN increased cellular p53 and Hdm2 levels. JS-K also increased p53 and Hdm2 levels in cells in a concentration-dependent manner as observed for ALLN (Figure 3a and b) . Next, to ensure the increase in Hdm2 level by JS-K is independent of p53 transactivation, p53
mouse embryo fibroblasts were transiently transfected with an Hdm2 plasmid under the control of a p53-independent CMV promoter. After this incubation, the cells were exposed to JS-K, and cellular Hdm2 levels were evaluated. Treatment of JS-K stabilized Hdm2 in cells in a dosedependent manner similar to that which was seen with ALLN ( Figure 3c ). These data suggest that JS-K stabilizes p53 and Hdm2 through inhibition of the E3 activity of Hdm2.
Earlier studies have shown that transformed cells are sensitive to apoptosis in response to p53. To evaluate whether JS-K induces differential killing of transformed cells, we compared parental RPE cells and RPE cells transformed with adenovirus E1A (RPE-E1A), which interacts with the retinoblastoma tumor suppressor gene product but not with p53 (Bandara and La Thangue, 1991; Yang et al., 2005) . Both cell types were treated with JS-K, and cell death was assessed by trypan blue exclusion. JS-K resulted in cell death in RPE-E1A cells, but had no measurable effect on parental RPE cells, similar to Adriamycin, a DNA-damaging chemotherapeutic agent known to induce p53 accumulation (Figure 4a ). To determine whether JS-K preferentially kills RPE-E1A cells by apoptosis, we assessed the cleavage of caspase substrate poly (ADP-ribose) polymerase (PARP) in JS-K-treated cells. JS-K induced PARP cleavage in RPE-E1A cells in a dose-dependent manner but not in RPE cells (Figure 4b ). These results indicate that JS-K preferentially induces cell apoptosis in transformed cells.
The ability of p53 to induce apoptosis is important in tumor suppression (Lowe et al., 1993a) . To evaluate whether the selective cell death of transformed cells correlates with p53, we used adenovirus E1A and Haras-transformed mouse embryo fibroblasts from p53
À/À mice (A9) (Lowe et al., 1993b) . Both cells were treated with JS-K, and cell viability was assessed. Although JS-K increased cell death in C8 cells in a concentration-dependent manner, JS-K did not induce cell death in A9 cells (Figure 4c ). JS-K also increased PARP cleavage in C8 cells but not in A9 cells (Figure 4d ), indicating that JS-K induces apoptotic cell death in a p53-dependent manner.
Cancer recurrence and chemotherapeutic resistance remain the major limitation to chemotherapy. Cisplatin is one of the most widely used chemotherapeutic drugs for cancer treatment (Turchi, 2006) . Recently, JS-K has been shown to induce cell death synergistically with cisplatin (Liu et al., 2004) . The proteasome inhibitor Bortezomib is also an anti-tumor drug for multiple myeloma cells (Adams, 2004) . JS-K has been reported to have a synergistic effect with Bortezomib on cell killing in multiple myeloma cells (Kiziltepe et al., 2007) . These findings indicate that JS-K, alone or in combination with other drugs, could be a useful compound for antitumor therapy.
Similar to JS-K, PABA/NO also inhibited the activity of ubiquitin E1. However, compared with JS-K, it took a significantly longer time period and higher concentrations of PABA/NO to achieve comparable levels of inhibition (Figure 1d ). With regard to NO generation, nucleophilic attack on JS-K produces a labile diazeniumdiolate ion that releases NO with simple, first-order kinetics. PABA/NO, on the other hand, is attacked by nucleophiles in two different positions; one leads to straightforward NO release as with JS-K, whereas the other, competing pathway cleaves the ester group to produce a phenolate intermediate whose capacity for NO generation is severely compromised . Therefore, the same number of PABA/NO molecules releases smaller amounts of NO compared with JS-K. À/À mdm2 À/À mice were transiently transfected with Hdm2 plasmid (Chen et al., 1995) . After 20 h of transfection, cells were treated with 50 mM ALLN or 1-10 mM JS-K for 8 h. Cellular Hdm2 and b-Actin were determined by immunoblotting.
We conclude that E1 is a target of NO release by JS-K. JS-K also leads to a decrease in total cellular ubiquitylation and an increase in cellular p53 levels. Moreover, JS-K selectively induces cell apoptosis in transformed cells expressing wild-type p53. Therefore, inhibition of E1 by JS-K could be responsible for the therapeutic effect of JS-K, which was observed in vitro and in animal models of tumors. These studies support the notion that targeting the ubiquitin system may represent a novel approach to the selective elimination of tumor cells retaining wild-type p53. 
